Abstract
Effects on survival in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was reported in The Lancet, and demonstrate that reductions in disease-specific mortality in this randomized control trial (RCT) indicate that ovarian cancer screening works. The UKCTOCS was large enough for sufficient accrual and follow-up, using two intervention arms: MMS (a multimodal strategy using the biomarker Ca125 combined with ultrasound as a secondary test) and USS (ultrasound alone) compared against a no-screen control group. MMS and USS performed similarly, showing a statistically significant reduction in mortality that increased with follow-up surveillance (8% reduction in years 0–7 vs 28% in years 7–14). The data led to the estimate that 641 screens are needed to prevent one ovarian cancer death.
Original language | English |
---|---|
Pages (from-to) | 475-479 |
Number of pages | 5 |
Journal | Women's Health |
Volume | 12 |
Issue number | 5 |
DOIs |
|
State | Published - Sep 2016 |
Bibliographical note
Publisher Copyright:© The Author(s) 2016.
Keywords
- Efficacy
- Mortality reduction
- Ovarian cancer screening
- Potential for effectiveness
- Ultrasound
ASJC Scopus subject areas
- Medicine (all)